Last reviewed · How we verify
Cipros 20 association
Cipros 20 association is a fixed-dose combination of ciprofloxacin and an additional agent designed to enhance antimicrobial efficacy.
Cipros 20 association is a fixed-dose combination of ciprofloxacin and an additional agent designed to enhance antimicrobial efficacy. Used for Bacterial infections (specific indications not clearly defined in available literature).
At a glance
| Generic name | Cipros 20 association |
|---|---|
| Also known as | EMS Association |
| Sponsor | EMS |
| Drug class | Fluoroquinolone antibiotic combination |
| Target | Bacterial DNA gyrase, topoisomerase IV |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
Cipros 20 association combines ciprofloxacin, a fluoroquinolone antibiotic that inhibits bacterial DNA gyrase and topoisomerase IV, with a complementary agent to broaden spectrum or improve therapeutic outcomes. The exact composition of the 'association' component is not clearly documented in standard pharmaceutical databases, limiting detailed mechanistic characterization.
Approved indications
- Bacterial infections (specific indications not clearly defined in available literature)
Common side effects
- Gastrointestinal disturbances
- Tendinopathy
- QT prolongation
- Photosensitivity
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Cipros 20 association CI brief — competitive landscape report
- Cipros 20 association updates RSS · CI watch RSS
- EMS portfolio CI